ClinicalTrials.gg
CompletedNCT06323928PROCEEDUpdated Jun 12, 2026

A Dose-finding Trial With Lu-AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive Treatments

A Phase 2 interventional study of Lu AG09222 and Placebo in Migraine, sponsored by H. Lundbeck A/S. Completed at 120 sites in 14 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-06-12.

Sponsored by H. Lundbeck A/S · Phase 2, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
874
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies in Migraine Disorders by H. Lundbeck A/S — 3 open to participants now, 3 under way, 3 of them phase 3. Migraine Disorders · H. Lundbeck A/S.

Enrollment
5th of 23
874 · median 237
Started
2024
with 2 others
Phase 2
3 of 23
none open now
Registered
21st of 23
by date

Among the 23 studies in Migraine Disorders by H. Lundbeck A/S, this one is the 5th largest by enrollment, is one of 3 that started in 2024, is one of 3 in phase 2, and was the 21st registered.

Migraine Disorders

1,660 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.

Browse Migraine Disorders studies →

Open to participants now

3 of the 23 studies in Migraine Disorders by H. Lundbeck A/S are open now, in 11 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Migraine Disorders by H. Lundbeck A/S, or all of them as a file.
02

Study summary

The purpose of this trial is to determine which doses of Lu AG09222 are recommended to help prevent migraines. People who join this trial have already tried 1 to 4 other available medications to prevent their migraines, but these medications have not helped them.

03

Conditions studied

  • Migraine

Keywords

  • Headache
  • Chronic Migraine
  • Episodic Migraine
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • The participant has a diagnosis of migraine as defined by International Classification of Headache Disorders Third Edition (ICHD-3) guidelines confirmed at the Screening Visit.
  • The participant has a history of migraine onset ≥ 12 months prior to the Screening Visit.
  • The participant has a migraine onset at ≤50 years of age.
  • The participant has ≥4 migraine days per month for each month within the past 3 months prior to the Screening Visit.
  • The participant has documented evidence of treatment failure in the past 10 years of at least 1 to 4 (maximum) different migraine preventive medications.

Key Exclusion Criteria:

  • The participant has previously been dosed with an anti-pituitary adenylate cyclase-activating peptide (anti-PACAP treatment).
  • The participant has confounding and pain syndromes.
  • The participant has a diagnosis of acute or active temporomandibular disorder.
  • The participant has a history or diagnosis of confounding headaches.

Additional protocol-defined criteria apply.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
874 participants (actual)

Study arms

  • Placebo comparator
    Group A: Placebo SC (closed for recruitment)

    Participants will receive 2 injections of placebo.

    Drug: Placebo

  • Experimental
    Group B: Lu AG09222 SC (closed for recruitment)

    Participants will receive 1 injection of placebo and 1 injection containing Lu AG09222.

    Drug: Lu AG09222 · Drug: Placebo

  • Experimental
    Group C: Lu AG09222 SC (closed for recruitment)

    Participants will receive 1 injection of placebo and 1 injection containing Lu AG09222.

    Drug: Lu AG09222 · Drug: Placebo

  • Experimental
    Group D: Lu AG09222 SC (closed for recruitment)

    Participants will receive 1 injection of placebo and 1 injection containing Lu AG09222.

    Drug: Lu AG09222 · Drug: Placebo

  • Experimental
    Group E: Lu AG09222 SC (closed for recruitment)

    Participants will receive 2 injections, each containing Lu AG09222.

    Drug: Lu AG09222

  • Placebo comparator
    Group F: Placebo IV

    Participants will receive placebo by intravenous (IV) infusion.

    Drug: Placebo

  • Experimental
    Group G: Lu AG09222 IV

    Participants will receive Lu AG09222 by IV infusion.

    Drug: Lu AG09222

  • Experimental
    Group H: Lu AG09222 IV

    Participants will receive Lu AG09222 by IV infusion.

    Drug: Lu AG09222

  • Experimental
    Group I: Lu AG09222 IV

    Participants will receive Lu AG09222 by IV infusion.

    Drug: Lu AG09222

Interventions

  • DrugBocunebartStudies of BocunebartBocunebart pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Lu AG09222 will be administered per the arm description.

  • DrugPlacebo

    Placebo matching to Lu AG09222 will be administered per the arm description

06

What researchers measure

Primary outcomes

  1. Change From Baseline in the Number of Monthly Migraine Days (MMDs)

    Time frame: Baseline up to Week 12 (Weeks 1-12)

Secondary outcomes

  1. Change From Baseline in MMDs

    Time frame: Baseline up to Week 12 (Weeks 1-12)

  2. Percentage of Participants With ≥50% Reduction From Baseline in MMDs

    Time frame: Baseline up to Week 12 (Weeks 1-12)

  3. Percentage of Participants With ≥75% Reduction From Baseline in MMDs

    Time frame: Baseline up to Week 12 (Weeks 1-12)

  4. Change from Baseline in the Number of Monthly Headache Days

    Time frame: Baseline up to Week 12 (Weeks 1-12)

  5. Number of Participants with Treatment-emergent Adverse Events (TEAEs)

    Time frame: Up to Week 20

  6. Number of Participants with Anti-drug Antibodies (ADA)

    Time frame: Up to Week 20

07

Study locations

120 sites
  • Accel Research Sites Network - Neurology and Neurodiagnostic of Alabama
    Hoover, Alabama 35244-5700, United States
  • Profound Research - Neurology Center of Southern California
    Carlsbad, California 92011, United States
  • Neurology Center of North Orange County
    Fullerton, California 92835, United States
  • CenExel CNS
    Los Alamitos, California 90720, United States
  • ASCLEPES Research Centers
    Sherman Oaks, California 91403, United States
  • Ki Health Partners LLC DBA New England Institute for Clinical Research
    Stamford, Connecticut 06905, United States
  • K2 Medical Research - Winter Garden
    Clermont, Florida 34711, United States
  • Clinical Neuroscience Solutions, Inc.
    Jacksonville, Florida 32256, United States
  • K2 Medical Research, LLC - Maitland
    Maitland, Florida 32751, United States
  • Aqualane Clinical Research
    Naples, Florida 34105, United States
  • K2 Medical Research Tampa LLC
    Tampa, Florida 33607, United States
  • Premiere Research Institute Palm Beach
    West Palm Beach, Florida 33407, United States
  • Accellacare and McFarland Clinic
    Ames, Iowa 50010, United States
  • Clinical Research Professionals
    Chesterfield, Missouri 63005, United States
  • Healthcare Research Network
    Hazelwood, Missouri 63042, United States
  • Dent Neurosciences Research Center, Inc.
    Amherst, New York 14226, United States
  • North Suffolk Neurology, PC.
    Port Jefferson Station, New York 11776, United States
  • Accellacare of Cary - Cary Medical Group
    Cary, North Carolina 27518, United States
  • Headache Wellness Center
    Greensboro, North Carolina 27405, United States
  • Raleigh Medical Group
    Raleigh, North Carolina 27609, United States
  • M3 Wake Research, Inc
    Raleigh, North Carolina 27612, United States
  • Accellacare of Rocky Mount
    Rocky Mount, North Carolina 27804, United States
  • Triad Neurological Associates
    Winston-Salem, North Carolina 27103, United States
  • Accellacare of Charleston
    Mt. Pleasant, South Carolina 29464, United States
  • Internal Medicine and Pediatric Associates of Bristol, PC
    Bristol, Tennessee 37620, United States
  • Cedar Health Research, LLC
    Dallas, Texas 75251, United States
  • Mercury Clinical Research
    Sugar Land, Texas 77478, United States
  • MedStar Health - Neurology Clinic at McLean
    McLean, Virginia 22101, United States
  • Diagnostic Consultative Center Convex Ltd
    Sofia, Sofiiska 1680, Bulgaria
  • MC Nevrocentrum
    Plovdiv, 4000, Bulgaria
  • University Multiprofile Hospital for Active Treatment Sveti Georgi
    Plovdiv, 4002, Bulgaria
  • MC Rusemed-OOD
    Rousse, 7000, Bulgaria
  • Neurosanatio s.r.o.
    Litomyšl, Pardubice Region 57001, Czechia
  • Dr. Radomir Talab MD, Office of
    Hradec Králové, 500 03, Czechia
  • Neuros s.r.o
    Pilsen, 30100, Czechia
  • Clintrial s. r. o.
    Prague, 100 00, Czechia
  • DADO MEDICAL s.r.o.
    Prague, 12000, Czechia
  • Praglandia s.r.o
    Prague, 150 00, Czechia
  • Axon Clinical s r.o
    Prague, 15500, Czechia
  • Neurologicka ordinace FORBELI sro
    Prague, 160 00, Czechia
  • Institut neuropsychiatricke pece
    Prague, 18600, Czechia
  • Neurologicka ambulance
    Slezská Ostrava, 710 00, Czechia
  • NeuroMed Zlin s.r.o.
    Zlín, 76001, Czechia
  • Bispebjerg Hospital - Region Capital
    Copenhagen, 2400, Denmark
  • Glostrup Hospital
    Glostrup Municipality, 2600, Denmark
  • Centre Hospitalier Universitaire de Lyon, Hopital Pierre Wertheimer
    Bron, 69500, France
  • Centre Hospitalier Universitaire de Clermont Ferrand - Gabriel Montpied
    Clermont-Ferrand Cedex1, 63003, France
  • Centre Hospitalier Regional Universitaire de Lille - Hopital Roger Salengro
    Lille, 59037, France
  • Assistance Publique Hopitaux de Marseille (AP-HM) - Hopital de La Timone
    Marseille, 13385, France
  • Assistance Publique - Hopitaux de Paris (AP-HP) - Hopital Lariboisiere
    Paris, 75010, France
  • Centre Hospitalier Universitaire (CHU) de Toulouse - Hopital Pierre-Paul Riquet
    Toulouse, 31059, France
  • Malkhaz Katsiashvili Multiprofile Emergency Medicine Center
    Tbilisi, 0101, Georgia
  • Caucasus Medical Center Ltd
    Tbilisi, 0102, Georgia
  • Archangel St Michael Multiprofile Clinical Hospital
    Tbilisi, 0159, Georgia
  • Jo Ann Medical Center
    Tbilisi, 0159, Georgia
  • JSC K. Eristavi National Center of Experimental and Clinical Surgery
    Tbilisi, 0159, Georgia
  • Aversi Clinic
    Tbilisi, 0160, Georgia
  • MD Georgia Staff Physician MediClub Georgia
    Tbilisi, 0160, Georgia
  • S. Khechinashvili University Hospital
    Tbilisi, 0179, Georgia
  • Charite - Universitaetsmedizin Berlin - Campus Charite Mitte (CCM)
    Berlin, 10117, Germany
  • Studienzentrum Dr. Bischof GmbH
    Böblingen, 71034, Germany
  • Klinik Haag i. OB
    Ebersberg, 85560, Germany
  • Headache Center Frankfurt
    Frankfurt, 65929, Germany
  • Siteworks - Hannover
    Hanover, 30449, Germany
  • Siteworks - Heidelberg
    Heidelberg, 69115, Germany
  • S-Medicon Kft.
    Budapest, Central Hungary (Közép-Magyarország) 1044, Hungary
  • Komarom-Esztergom Varmegyei Szent Borbala Korhaz
    Tatabánya, 2800, Hungary
  • Jinnouchi Neurosurgery Clinic
    Kasuga-shi, Fukuoka 816-0802, Japan
  • Ikeda Neurosurgery Clinic
    Kasuga-shi, Fukuoka 816-0824, Japan
  • Nakamura Memorial Hospital
    Sapporo, Hokkaido 060-0061, Japan
  • Mito Kyodo General Hospital
    Mito, Ibaraki 310-0015, Japan
  • Iwate Medical University Uchimaru Medical Center
    Morioka, Iwate 020-8505, Japan
  • Tanaka Neurosurgery & Headache Clinic
    Kagoshima, Kagoshima-ken 890-0052, Japan
  • Atsuchi Neurosurgical Hospital
    Kagoshima, Kagoshima-ken 892-0842, Japan
  • Shonan Keiiku Hospital
    Fujisawa-shi, Kanagawa 252-0816, Japan
  • Sendai Headache and Neurology Clinic Medical Corporation
    Sendai, Miyagi 982-0014, Japan
  • Tominaga Hospital
    Osaka, Osaka 556-0017, Japan
  • Saitama Medical University Hospital
    Iruma-gun, Saitama 350-0495, Japan
  • Japanese Red Cross Shizuoka Hospital
    Shizuoka, Shizuoka 420-0853, Japan
  • Dokkyo Medical University Hospital
    Shimotsuga-Gun, Tochigi 321-0293, Japan
  • Shinagawa Strings Clinic
    Minato-ku, Tokyo 108-0075, Japan
  • Kitasato University Kitasato Institute Hospital
    Minato-ku, Tokyo 108-8642, Japan
  • Keio University Hospital
    Tokyo, 160-8582, Japan
  • Hospital of Lithuanian University of Health Sciences Kaunas
    Kaunas, 50161, Lithuania
  • Klaipeda¿s University Hospital
    Klaipėda, LT-92288, Lithuania
  • Medicum Centrum
    Tauragė, 72250, Lithuania
  • Vilniaus Universiteto Medicinos Fakultetas - Neurologijos ir Neurochirurgijos Klinika - Neurologi...
    Vilnius, 08661, Lithuania
  • Centrum Medyczne HCP sp. z o.o
    Poznan, Greater Poland Voivodeship 61-485, Poland
  • Landa Specjalistyczne Gabinety Lekarskie
    Krakow, Lesser Poland Voivodeship 31-156, Poland
  • Centrum Medyczne Neuroprotect
    Warsaw, Masovian Voivodeship 01-684, Poland
  • Neuro-Care sp. z o.o. sp. Komandytowa
    Katowice, Silesian Voivodeship 40-749, Poland
  • Centrum Medczyne Pratia Bydgoszcz
    Bydgoszcz, 85-796, Poland
  • Centrum Kliniczno-Badawcze J.Brzezicki, B.Gornikiewicz-Brzezicka Lekarze Spolka partnerska
    Elblag, 82-300, Poland
  • Pratia MCM Krakow
    Krakow, 30-727, Poland
  • Centrum Opieki Zdrowotnej OrkanMed
    Ksawerów, 95-054, Poland
  • Appletreeclinics Network Sp. z o.o.
    Lodz, 90-347, Poland
  • Clinirem Sp. z o.o.
    Lublin, 20-064, Poland
  • Indywidualna Praktyka Lekarska Dr hab. n. med. Anna Szczepanska-Szerej
    Lublin, 20-582, Poland
  • Centrum Medyczne Hope Clinic Sebastian Szklener
    Lublin, 20-701, Poland
  • Twoja Przychodnia NCM
    Nowa Sól, 67-100, Poland

Showing the first 100 of 120 sites across 14 countries. Choose a country and city above to see the rest.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2024 to primary completion in Jan 2026, 21 months.

Of 43 industry-sponsored phase 2 interventional studies under Migraine Disorders, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 20. This study's 21 months is above that.

Counting every sponsor, half of 73 studies reached it within 15 months; a quarter within 11 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 15, 2024
First posted
Mar 21, 2024
StartActual
Apr 1, 2024
Primary completionActual
Jan 16, 2026
CompletionActual
Mar 16, 2026
Last update
Jun 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06323928
Lead sponsor
H. Lundbeck A/S
Responsible party
Sponsor
First posted
Mar 21, 2024
Start date
Apr 1, 2024
Primary completion
Jan 16, 2026
Completion
Mar 16, 2026
Last update
Jun 12, 2026

Study contacts

Email contact via H. Lundbeck A/S
study director · H. Lundbeck A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bocunebart

Start the discussion